10x Genomics, Inc. (TXG)
Nasdaq: TXG · Laboratory Analytical Instruments · Pleasanton, CA · filing with the SEC since 2019
Grade6.3
◀ Past 6.1● Present 6.5▶ Future 6.3
Who owns 10x Genomics, Inc.
As filed with the SECHolders of 5% or more
6
Fmr LLC holds 15.6% of CLASS A COMMON STOCK, as its SCHEDULE 13G/A filed Mar 6, 2026 says.
Directors and officers
9
report now, of 15 people on the record since 2019. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 6 named at left.
Holders of 5% or moreshare of the class, as filed
Fmr LLC
SCHEDULE 13G/A · filed Mar 6, 2026 · CLASS A COMMON STOCK · 10.8% in Jan 8, 2026
T. Rowe Price Associates, Inc.
SCHEDULE 13G · filed Sep 8, 2026 · COMMON STOCK
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 16, 2025 · Common Stock
Vanguard Portfolio Management
SCHEDULE 13G · filed Apr 28, 2026 · Common Stock
Vanguard Capital Management
SCHEDULE 13G · filed Apr 29, 2026 · Common Stock
ARK Investment Management LLC
SCHEDULE 13G/A · filed Oct 7, 2026 · Class A Common Stock, $0.00001 par value per share · 8.56% in Aug 14, 2026
Amova Asset Management Americas, Inc.
SCHEDULE 13G/A · filed Nov 13, 2025 · Class A common stock, par value $0.00001 per share · reported falling below 5%, from 5.4% in Aug 13, 2025
Sumitomo Mitsui Trust Group, Inc.
SCHEDULE 13G/A · filed Oct 27, 2025 · Class A common stock, par value $0.00001 per share · reported falling below 5%, from 5.4% in Jul 31, 2025
Millennium Management LLC
SCHEDULE 13G/A · filed Aug 12, 2025 · Class A Common Stock, par value $0.00001 per share · reported falling below 5%, from 5.1% in Apr 4, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 25, 2026 · Common Stock · reported falling below 5%, from 0% in Mar 24, 2026
What TXG reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Scale BioScience Inc. Acquisition
A company bought · asset acquisition · owns, named in the 10-K filed Feb 13, 2026
Insider tradesForm 4
50sales
0purchases
34sales on a scheduled plan
6people selling
$16.9Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window6 of 35 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Saxonov Serge | Chief Executive Officer | 22 | $6.8M | 19 | 0 | $0 |
| Taich Adam | Chief Financial Officer | 7 | $4.8M | 3 | 0 | $0 |
| Stuelpnagel John R | director | 5 | $2.4M | 0 | 0 | $0 |
| Hindson Benjamin J. | Title: President and Chief Scientific Officer | 4 | $1.5M | 0 | 0 | $0 |
| Suliman Shehnaaz | director | 9 | $800,000 | 9 | 0 | $0 |
| Teichmann Sarah A. | director | 3 | $600,000 | 3 | 0 | $0 |